Trials / Completed
CompletedNCT02225704
Radium-223 in Combination With Enzalutamide
A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Cancer Trials Ireland · Network
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 and enzalutamide |
Timeline
- Start date
- 2015-06-03
- Primary completion
- 2017-07-01
- Completion
- 2021-11-23
- First posted
- 2014-08-26
- Last updated
- 2026-04-13
Locations
7 sites across 1 country: Ireland
Source: ClinicalTrials.gov record NCT02225704. Inclusion in this directory is not an endorsement.